Structure via PubChem · Public domain (PubChem)
osimertinib
Sign in to saveAlso known as AZD 9291, AZD-9291, AZD9291, mereletinib (obsolete INN), Tagrisso®, Mereletinib, N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide
Osimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.
Key facts
- Drug.image
- Osimertinib.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 250
- Drug.USAN
- osimertinib mesylate
- Drug.JAN
- osimertinib mesilate
- Drug.tradename
- Tagrisso, others
- Drug.MedlinePlus
- a616005
- Drug.DailyMedID
- Osimertinib
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- EB04
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.protein_bound
- Probably high
- Drug.metabolism
- Oxidation (CYP3A)
via Wikipedia infobox
Chemical data
- Formula
- C28H33N7O2
- Molecular weight
- 499.6 g/mol
- IUPAC name
- N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide
- SMILES
- CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC
- InChIKey
- DUYJMQONPNNFPI-UHFFFAOYSA-N
- XLogP
- 3.7
- Polar surface area
- 87.6 Ų
- H-bond donors
- 2
- H-bond acceptors
- 7
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2015
- Admin. routes
- oral
- Indications
- non-small cell lung carcinoma, neoplasm, adenocarcinoma, squamous cell carcinoma
via ChEMBL · EBI
Research
4,370 papers- Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance.Journal of hematology & oncology · 2022
- Acquired resistance mechanisms to osimertinib: The constant battle.Cancer treatment reviews · 2023
- A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.Scientific reports · 2022
- MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2024
- Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance.Japanese journal of clinical oncology · 2023
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 499.27
- Has use
- medication
Show 5 more facts
- chemical formula
- C₂₈H₃₃N₇O₂
- canonical SMILES
- CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC
- subject has role
- antineoplastic
- physically interacts with
- epidermal growth factor receptor
- Commons category
- Osimertinib
Sources (6)
via Wikidata · CC0
~7 min read
Encyclopedic overview
10 sectionsContents
- Medical uses
- Adverse effects
- Interactions
- Pharmacology
- Chemistry
- History
- Society and culture
- Economics
- See also
- References
{{Infobox drug | verifiedrevid = | image = Osimertinib.svg | image_class = skin-invert-image | width = 250 | alt = | USAN = osimertinib mesylate | JAN = osimertinib mesilate
| tradename = Tagrisso, others | Drugs.com = | MedlinePlus = a616005 | DailyMedID = Osimertinib | pregnancy_AU = D | routes_of_administration = By mouth | ATC_prefix = L01 | ATC_suffix = EB04
Excerpted from Wikipedia’s “osimertinib” article, available under the CC BY-SA 4.0 licence.